No more painful insulin shots: Hyderabad company develops oral insulin spray for diabetes
NiedlFree Technologies, a company affiliated with Transgene Biotek, has made significant progress in the field of diabetes treatment. They claim to have developed a painless and needle-free oral insulin spray called Ozulin, which can be used by both animals and humans. This breakthrough could potentially make controlling blood sugar levels as simple as spraying insulin into the mouth, a TOI report stated.
NiedlFree Technologies has applied to the Central Drugs Standard Control Organisation (CDSCO) for permission to conduct safety and toxicology studies before proceeding with human clinical trials. Dr. K Koteswara Rao, the co-founder and director of NiedlFree Technologies and CMD of Transgene Biotek, revealed that the company has obtained global patents for Ozulin in over 40 countries.
In addition to diabetes treatment, NiedlFree Technologies is also working on developing oral and nasal sprays for cancer, osteoporosis, and Alzheimer's.
To bring these drugs to the market, the company plans to raise $225-250 million in funding over the next few years.
Dr. Rao emphasized the potential impact of Ozulin on diabetes care, stating that the global market for Type 1 and Type 2 diabetes treatment is estimated to be around $78 billion by 2022. In a recent study conducted by Palamur Biosciences on dogs, Ozulin demonstrated a bioavailability of over 91% compared to injectable insulin.
This promising result indicates the effectiveness of the oral insulin spray.
Dr. Rao explained that NiedlFree Technologies achieved this breakthrough by encapsulating human insulin into functionalized nano particles, ensuring optimal delivery into the bloodstream with a prolonged release. Many biopharma companies worldwide have attempted to develop
